First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
Status:
Recruiting
Trial end date:
2023-09-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination
with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors